共 8 条
[1]
Circumvention of P-glycoprotein-mediated multidrug resistance by S16020-2: kinetics of uptake and efflux in sensitive and resistant cell lines[J] . A. Pierré,S. Léonce,V. Pérez,G. Atassi.Cancer Chemotherapy and Pharmacology . 1998 (6)
[2]
In vitro cytotoxicity of S16020-2, a new olivacine derivative[J] . Stéphane Léonce,Valérie Perez,Marie-Rose Casabianca-Pignede,Monique Anstett,Emile Bisagni,Alain Pierré,Ghanem Atassi.INVESTIGATIONAL NEW DRUGS . 1996 (2)
[3]
Using yeast to study resistance to topoisomerase II-targeting drugs[J] . John L. Nitiss.Cancer Chemotherapy and Pharmacology . 1994 (1)
[4]
Topoisomerase poisoning activity of novel disaccharide anthracyclines. Guano F, Pourquier P, Tinelli S, et al. Molecular Pharmacology . 1999
[5]
Induction of apoptosis in human leukemia K562 and gastric carcinoma SGC-7901 cells by salvicine, a novel anticancer compound. Qing C, Jiang C, Ding J. Anti Cancer Drugs . 2001
[6]
Synthesis and antitumor activity of novel diterpene quinone salvicine and the analogs. Zhang J, Ding J, Tang Q, et al. Bioorg Medi Chem Lett . 1999
[7]
Cellular resistance to the antitumor DNA topoisomerase Ⅱinhibitor S16020-2: impor-—286—tance of the N-[2 (Dimethylamino) ethyl] carbamoyl side chain. Le MS, Chaminade F, Delaporte C, et al. Molecular Pharmacology . 2000
[8]
Molecular interactions of DNA-topoisomerase I and Ⅱ inhibitor with DNA and topoisomerases and in ternary complexes: binding modes and biological effects for intoplicine derivatives. Nabiev I, Chourpa I, Riou JF, et al. Biochemistry . 1994